

# EXHIBIT 2

# Lack of Promiscuity in Autoantigen-Specific H and L Chain Combinations as Revealed by Human H and L Chain "Roulette"<sup>1</sup>

Stefano Portolano,<sup>2\*</sup> Gregorio D. Chazenbalk,\* J. Scott Hutchison,<sup>†</sup>  
Sandra M. McLachlan,\* and Basil Rapoport\*

\*Thyroid Molecular Biology Unit, Veterans' Administration Medical Center and the University of California, San Francisco, CA 94121 and <sup>†</sup>Nichols Institute, San Juan Capistrano, CA 92690

**ABSTRACT.** Individual H or L chains from a human autoantibody were used to search for other L or H chains that could form antigen-binding fragments, Fab, with the same specificity. The parent Fab (SP1.2) exhibits high affinity binding for thyroid peroxidase (TPO), a 107-kDa protein that is the major autoantigen in human autoimmune thyroiditis. This autoantibody "roulette," performed by using Ig H and L chain gene libraries expressed in bacteria, increased the frequency of TPO-binding clones in the new libraries. However, the frequency was still much lower than would be the case if promiscuous combinations with a variety of H or L chains were compatible with specific Ag binding. Nucleotide sequence analysis of the H and L chains of the new TPO-binding clones revealed even more restriction. Thus, with the SP1.2 H chain, all 11 new Fab utilized L chains from the same V<sub>H</sub>1 family germline gene as SP1.2 itself. Similarly, five of six H chains "captured" by the SP1.2 L chain were very closely related to the SP1.2 H chain. However, one totally different H chain was isolated: SP4.6 has a V<sub>H</sub> region that differs substantially from that of SP1.2. SP4.6 also has a distinct D region, uses a different J<sub>H</sub>, and, unlike SP1.2, which is an IgG1, belongs to subclass IgG4. The affinities for TPO of SP4.6 (with the different H chain) and SP1.20 (which had the least mutated L chain germline gene) were similar to that of SP1.2 (~10<sup>-10</sup> M). As expected, the SP1.2 and SP1.20 Fab, which have the same H chain and closely related L chains, bound to the same domain on TPO. However, a similar domain on TPO was recognized by both SP4.6 and SP1.2, despite the fact that their V, D, and J regions are quite different. This observation raises the possibility that the L chain is critical in defining epitope specificity, even in the presence of completely different D regions and nonidentical V<sub>H</sub> regions. *Journal of Immunology*, 1993, 150: 880.

A hallmark of autoimmune thyroid destruction in humans is the presence in serum of high affinity IgG class autoantibodies to TPO,<sup>3</sup> the primary enzyme involved in thyroid hormone synthesis (reviewed in Reference 1). TPO is a glycoprotein of ~107 kDa expressed on the surface of thyroid cells (reviewed in Reference 1). Human autoantibodies to TPO are not mon-

oclonal, as evidenced by the contribution of different IgG subclasses and L chain types in the same patient (2, 3).

We have cloned three human IgG1/κ autoantibodies (SP1.2, SP1.4, and SP1.5; previously called SP2, -4, and -5) that bind TPO specifically and with high affinity (4, 5). These autoantibodies were obtained by expressing random combinations of H and L chain Ig genes as Ag-binding fragments, Fab, in a bacteriophage λ library (6) (Fig. 1A). The cDNA in this library was prepared from B cells infiltrating the thyroid gland of a patient with autoimmune

Received for publication July 15, 1992. Accepted for publication November 3, 1992.


The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

<sup>1</sup> This research was supported by National Institutes of Health Grants DK-36182 and EY-09498.


<sup>2</sup> Address correspondence and reprint requests to Stefano Portolano, M.D., Veterans' Administration Medical Center, Thyroid Molecular Biology Unit (111T), 4150 Clement Street, San Francisco, CA 94121.

<sup>3</sup> Abbreviation used in this paper: TPO, thyroid peroxidase.

A



B



**FIGURE 1.** A, Outline of the approach (6) used to construct parent H and L chain libraries and the combinatorial library from which TPO-specific Fab SP1.2, SP1.4, and SP1.5 were obtained (4, 5). B, combinatorial libraries constructed by using SP1.2 H (or L) chain with the parent L (or H) chain. PCR, polymerase chain reaction.

thyroid disease. The three TPO autoantibody Fab share the identical Ig H chain. The L chains are not the same but are derived from the same  $V_{\kappa}$  germline gene, HSIKLO12 (7).

Because of the random nature of the H and L chain combinations in our cDNA library, the question arose as to whether the SP Fab autoantibody H chain (or L chain) could combine with a variety of other L chains (or H chains) in the parent library and still bind to TPO. Therefore, we used the SP1.2 H (or L chain) to search for other L (or H) chains in the parent libraries that could form a Fab capable of binding TPO (Fig. 1B). Recently, following a similar approach, it has been reported that there is notable promiscuity in the H and L chain combinations of murine Fab that bind the hapten nitrophenyl phosphoramidate (8). In contrast, our "roulette" experiments demonstrate more restriction in the H and L chain combinations for high affinity binding to a human autoantigen, TPO.

## Materials and Methods

### Library construction and screening

The plasmid of clone SP1.2 (4) was digested with *Xho*I and *Spe*I to release the H chain cDNA insert. Similarly, the L chain cDNA fragment was obtained by *Xba*I and *Sac*I digestion. The inserts were gel purified and ligated into ImmunoZap H and L arms (Stratagene, La Jolla, CA),

respectively, to generate a clonal SP1.2 H chain library and a clonal SP1.2 L chain library, respectively (Fig. 1B). These libraries were amplified and the DNA was extracted as described (4). The DNA from the SP1.2 H chain library was digested with *Hind*III followed by *Eco*RI and was ligated with the DNA prepared from the original L chain library (4). Similarly, the DNA from the SP1.2 L chain library was digested with *Mlu*I followed by *Eco*RI and was ligated with the DNA from the original H chain library (4). The original H and L libraries contained >80% inserts of the correct size. The combinatorial libraries were screened in XL1-Blue cells by conventional techniques (9), by using secreted human rTPO (10) that had been labeled with  $^{125}$ I (to a specific activity of 10 to 20  $\mu$ Ci/ $\mu$ g of protein) by the Iodogen method (11). TPO-binding plaques were cloned to homogeneity and plasmids were excised from the ImmunoZap bacteriophage by using the helper phage R408, according to the Stratagene protocol. Nucleotide sequencing of the cDNA inserts was performed by the dideoxynucleotide chain termination method (12).

### Fab expression

Fab were expressed as soluble proteins in XL1-Blue cells, as described previously (5). In brief, protein synthesis was induced with 1 mM isopropylthiogalactopyranoside (Sigma Chemical Co., St. Louis, MO) for 1 h at 37°C. The

Table 1  
Frequencies of  $^{125}\text{I}$ -TPO-binding clones in roulette of SP1.2  
H and L chains

| Fab Combinatorial Library         | Frequency | Plaques Screened |
|-----------------------------------|-----------|------------------|
| SP H chain $\times$ SP L chain    | 1:60,000  | 180,000          |
| SP1.2 L chain $\times$ SP H chain | 1:5,000   | 30,000           |
| SP1.2 H chain $\times$ SP L chain | 1:500     | 15,000           |

cells were then pelleted, frozen at  $-20^{\circ}\text{C}$ , and resuspended in 0.02 volumes of 10 mM Tris, pH 8.0, containing 2  $\mu\text{g}/\text{ml}$  aprotinin, 1  $\mu\text{g}/\text{ml}$  leupeptin, 1  $\mu\text{g}/\text{ml}$  pepstatin, and 0.1 mM PMSF (all from Sigma). The suspension was sonicated, membranes were pelleted by centrifugation at  $4000 \times g$ , and the Fab were affinity purified from the supernatant by using a protein G-Sepharose column (Pharmacia, Piscataway, NJ).

#### Fab binding of $^{125}\text{I}$ -TPO

As described previously (5), Fab diluted in assay buffer (0.15 M NaCl containing 10 mM Tris-HCl, pH 7.5, and

0.5% BSA) were incubated with  $^{125}\text{I}$ -TPO ( $\sim 25,000$  cpm) and mouse mAb to human  $\kappa$  L chains (QE11; Recognition Sciences, Birmingham, UK), in a total volume of 200  $\mu\text{l}$ . After 1 h at room temperature, 100  $\mu\text{l}$  of Sac-cel (donkey anti-mouse Ig covalently coupled to cellulose; IDS, Boldon, Tyne, and Wear, UK) were added, and the incubation was continued for 30 min. After addition of 1 ml of assay buffer and vortexing, the mixture was centrifuged for 5 min at  $1000 \times g$  to sediment the immune complexes, which were then counted to determine the percentage of radiolabeled TPO bound. The affinities of the Fab for TPO were determined by Scatchard analysis (13) from values obtained in the presence of increasing concentrations of unlabeled TPO. The data presented are the mean  $\pm$  SEM of triplicate determinations.

#### Competition between Fab for binding to TPO

One Fab was immobilized by incubation (total volume, 200  $\mu\text{l}$ ) with murine mAb anti-human  $\kappa$  (QE11) for 1 h at room temperature. After incubation with 100  $\mu\text{l}$  of Sac-cel

FIGURE 2. A, Nucleotide sequences of the  $V_H$  region of TPO-specific Fab SP1.2 and SP4.6, compared with germ-line genes hv1L1 (16) and 1-1 (14). B, derived amino acid sequence (in single-letter code) of the  $V_H$  regions of SP1.2 and SP4.6, again in comparison with hv1L1 and 1-1. In A and B, dots represent identical nucleotides or amino acids, respectively. CDR and framework regions (FW) are indicated according to Kabat et al. (26). C, nucleotide and derived amino acid sequences of the SP4.6 D region. These sequence data are available from GenBank (accession number M82813 for SP1.2) and from EMBL (accession number Z15084 for SP4.6).

|   |  |
|---|--|
| <b>A</b>                                  |  |
| <b>FW1</b>                                |  |
| hv1L1                                     | CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAACAAGCCTGGGGCTCAGTGAAGCTCTCCTGCAAGGCTT |
| 1-1                                       | .....C.....G...T.....  |
| SP1.2                                     | .....A.A...C.CG.....G.....   |
| SP4.6                                     | .....A.A...C.CG.....T...G...C.....G.....                                 |
| <b>CDR1</b>                               |  |
| hv1L1                                     | CTGGAGACACCTTCACCG   |
| 1-1                                       | .....T.....  |
| SP1.2                                     | .....T.....C.....  |
| SP4.6                                     | .....T.....A...A...C...G.T.....  |
| <b>FW2</b>                                |  |
| hv1L1                                     | GTGGCAGCGCCCTGGACAAGGCTTCAGTGGA  |
| 1-1                                       | .....  |
| SP1.2                                     | .....  |
| SP4.6                                     | .....  |
| <b>CDR2</b>                               |  |
| hv1L1                                     | TGGGA TGGATCAACCTTAACAGTGGTGGCACAACCTATGCACAGAAGTTTCAGGGC AGGGTCACCATG   |
| 1-1                                       | .....C.....  |
| SP1.2                                     | .....A...G.....A...C...GG.T.....   |
| SP4.6                                     | .....G.A...C...G.GA...T.C.....   |
| <b>FW3</b>                                |  |
| hv1L1                                     | ACCAGGGACACGTCATCAGCACAGCCTACATGGAGCTGAGCAGGCTGAGATCTGACGACAGGCCCTGTAT   |
| 1-1                                       | .....A.....  |
| SP1.2                                     | .....C.....T.A...T.....G.C...T.....                                      |
| SP4.6                                     | .....A...G...G...T...C...C...A...G...C...C...                            |
| <b>CDR3</b>                               |  |
| hv1L1                                     | TACTGTGGGAGA   |
| 1-1                                       | .....  |
| SP1.2                                     | .....C.....  |
| SP4.6                                     | .....C.....  |
| <b>B</b>                                  |  |
| <b>FW1</b>                                |  |
| hv1L1                                     | QVQLVQSGAEVNPFGASVKVSCASGDTFT  |
| 1-1                                       | .....R...K.S.....Y...  |
| SP1.2                                     | .....K.LE...K.....Y...   |
| SP4.6                                     | .....K.LE...LKN...R...Y..N   |
| <b>CDR1</b>                               |  |
| hv1L1                                     | GYMHW  |
| 1-1                                       | .....  |
| SP1.2                                     | .....H...  |
| SP4.6                                     | .....D.HV...   |
| <b>FW2</b>                                |  |
| hv1L1                                     | VRQAPGQGLEWNG  |
| 1-1                                       | .....  |
| SP1.2                                     | .....I...  |
| SP4.6                                     | .....V...  |
| <b>CDR2</b>                               |  |
| hv1L1                                     | WINFNSGGTNYAQKFGQ  |
| 1-1                                       | .....  |
| SP1.2                                     | .....S...R.A.RF.....   |
| SP4.6                                     | .....KNA...R.S.....  |
| <b>FW3</b>                                |  |
| hv1L1                                     | RVTMTSDTSISTAYMELSLRSDDTAVYYCAR  |
| 1-1                                       | .....K.....  |
| SP1.2                                     | .....S...N.V...G.F.....T   |
| SP4.6                                     | .....A...A...TS.K.....   |
| <b>C</b>                                  |  |
| SP4.6 GGC CTA GGA GTT GGT ACG TGG GCC CTT |  |
| C V C V C T W G L                         |  |

(30 min at room temperature), the complexes were diluted in assay buffer (see above) and centrifuged at  $1000 \times g$  (5 min at  $4^\circ\text{C}$ ). The pellets were resuspended in normal human serum diluted 1/30 in assay buffer, to saturate remaining anti- $\kappa$  binding sites. In a separate set of tubes, increasing concentrations of "free" Fab were preincubated with  $^{125}\text{I}$ -TPO for 1 h at room temperature. Aliquots (100  $\mu\text{l}$ ) were then incubated for 30 min with the immobilized Fab pellets and washed with assay buffer, and radioactivity bound to the Sac-cel was counted. Nonspecific binding ( $\sim 2\%$  of total counts added) was subtracted to provide values for specific binding to TPO.

## Results

### Frequencies of $^{125}\text{I}$ -TPO-binding clones

Combining the L chain of SP1.2 with the SP parent H chain library yielded a combinatorial library of  $\sim 10^7$  PFU (SP1.2 L  $\times$  H library). Similarly, the combination of the SP1.2 H chain with the SP parent L chain library resulted in a library of  $\sim 10^7$  PFU (SP1.2 H  $\times$  L). As expected, this "roulette" with either the SP1.2 L or H chain led to a greater frequency of TPO-binding clones than was detected in the original screening of the parent library (Table I). Further, the frequency of TPO-binding clones was 10-fold greater in the SP1.2 H  $\times$  L library than in the SP1.2 L  $\times$  H library.

### TPO-binding clones from the SP1.2 L $\times$ H library

We originally reported (4) that the  $V_H$  of SP1.2 appears to be derived from the  $V_{H1}$  family germline gene 1-1 (14).  $V_{H1}$ -1 was first reported to be a pseudogene, but other investigators have suggested that 1-1 is a functional gene (15). More recently, another  $V_{H1}$  germline gene, hv1L1, has been described (16) that is closely related to 1-1. At the nucleotide level, SP1.2 is more homologous to hv1L1 (93%) than to 1-1 (90%) (Fig. 2A).

Determination of the nucleotide sequences of the six new TPO-binding clones isolated from the SP1.2 L  $\times$  H library revealed that the VDJ regions of five (SP1.7 to -11) are almost identical to those of the original SP1.2 (Table II). In the  $V_H$  region, three clones (SP1.9, SP1.10, and SP1.11) are identical to SP1.2 H chain and two clones (SP1.7 and SP1.8) differ from the original SP1.2 H chain by only one amino acid (proline and leucine for Ala-24, respectively). The D regions of SP1.7 to -11 are identical and differ from the SP1.2 D region by a single silent base substitution. The J regions of SP1.7 to -11 are of the  $J_{H6}$  family (15). Re-examination of the SP1.2 DJ regions indicates that this clone, too, is a  $J_{H6}$  (rather than a  $J_{H3}$ ) combined with a very short D region.

One of the six new clones (SP4.6) from the SP1.2 L  $\times$  H library differs more substantially from SP1.2 as well as from SP1.7 to -11 (Table II). Both SP4.6 and SP1.2 are members of the  $V_{H1}$  family and may be derived from the

TABLE II  
Characteristics at the nucleotide level of 17 TPO-binding clones in roulette of SP1.2 H and L chains<sup>a</sup>

| SP1.2 L $\times$ H (6 clones)  | $V_H$ (%)       | D         | $J_H$ | Subclass |
|--------------------------------|-----------------|-----------|-------|----------|
| SP1.7; -1.8                    | 94              | SP1.2     | 6     | IgG1     |
| SP1.9; -1.10; -1.11            | 94 <sup>b</sup> | SP1.2     | 6     | IgG1     |
| SP4.6                          | 90              | Non-SP1.2 | 4     | IgG4     |
| SP1.2 H $\times$ L (11 clones) | $V_K$ (%)       |           | $J_K$ |          |
| SP1.17; -1.19                  | 92 <sup>c</sup> |           | 2     |          |
| SP1.14; -1.15; -1.22           | 93 <sup>d</sup> |           | 2     |          |
| SP1.21                         | 93 <sup>d</sup> |           | ?     |          |
| SP1.12                         | 94              |           | 1     |          |
| SP1.13                         | 93              |           | 2     |          |
| SP1.16                         | 92              |           | 2     |          |
| SP1.18                         | 93              |           | 2     |          |
| SP1.20                         | 95              |           | 1     |          |

<sup>a</sup> Homology of  $V_H$  and  $V_L$  genes is calculated for putative germline genes hv1L1 and HSIKLO12, respectively. The D regions are described as resembling SP1.2 (4) or not resembling SP1.2 (Fig. 2C).

<sup>b</sup> 100% homologous with SP1.2 H.

<sup>c</sup> 100% homologous with SP1.2 L.

<sup>d</sup> Identity of  $V_K$  for SP1.14, SP1.15, SP1.22, and SP1.21.

germline gene hv1L1 (16) (Fig. 2A). However, there are major differences (24 amino acids) in the  $V_H$  regions of SP4.6 and SP1.2 (Fig. 2B). In addition, the SP4.6 D region (Fig. 2C) is quite different from that of SP1.2 and does not resemble any published D region sequence. Further, the SP4.6 J region is a  $J_{H4}$  truncated at its 5' end. The most surprising finding was that the hinge region sequence indicates that SP4.6 is an IgG4, in contrast to SP1.2 and SP1.7 to -11, which are IgG1. The C region primer used for the polymerase chain reaction in constructing the SP H chain parent library (CH1; Stratocyte, San Diego CA) is described as an IgG1 primer with the capacity to cross-prime with other IgG subclasses.

### TPO-binding clones from the SP1.2 H $\times$ L library

The nucleotide sequences of the L chains were determined in 11 TPO-binding clones in the SP1.2 H  $\times$  L library (Table II; Fig. 3). At the amino acid level, the  $V_K$  regions of nine clones are very similar to, and two clones (SP1.17 and SP1.19) are identical to, the original SP1.2 L chain (Fig. 4A). Four of the nine clones (SP1.14, SP1.15, SP1.21, and SP1.22) have identical  $V_K$  regions. All 11 new L chain clones appear to be derived from the  $V_K$  germline gene HSIKLO12 (7). This gene is almost identical to HUMIGKLVJ (17), with which we originally compared SP1.2 (4). SP1.20 is the closest (95%) to the putative germline gene (Table II). The  $J_K$  regions of 10 of the 11 new clones belong to  $J_{K1}$  or  $J_{K2}$  (Fig. 4B). We cannot assign the  $J_K$  region of SP1.21. SP1.14, SP1.15, and SP1.22 have identical  $V_K$  and  $J_K$  sequences. Because clones SP1.17 and SP1.19 have  $J_{K2}$  regions (like SP1.2) these clones are, overall, identical to SP1.2.

**FIGURE 3.** Nucleotide sequences of the  $V_K$  regions of TPO-specific Fab SP1.12 through SP1.22, compared with the closest germline gene, HSIGKLO12 (7). The sequence of clone SP1.14 is identical to those of SP1.15, SP1.21, and SP1.22. Clone SP1.17 is identical to SP1.19 and both have the same sequence as SP1.2. *Dots*, identical nucleotides. CDR and framework regions (FW) are indicated according to Kabat et al. (26). These sequence data are available from EMBL under accession numbers Z15073 to Z15083 (SP1.12 to SP1.22).

|           |                     | FW1   |                |                         |
|-----------|---------------------|---|----------------|-------------------------|
| HSIGKLO12 |                     | GACATCCAGATGACCCAGTCTCCATGCTCCCTGTCTGCTAGGAGACAGACTCACCATCAC    |                |                         |
| SP #      | 12                  | .GC .GT . . . . .   | GG . . . . .   | C . . . . .             |
|           | 20                  | .GC .GT . . . . .   | . . . . .      | G . . . . .             |
|           | 18                  | .GC .GT . . . . .   | TT . . . . .   | AG . . . . .            |
|           | 14                  | .GC .GT . . . . .   | . . . . .      | G . . . . .             |
|           | 13                  | .GC .GT . . . . .   | . . . . .      | A . . . . .             |
|           | 16                  | .GC .GT . . . . .   | T . . . . .    | . . . . .               |
|           | 17                  | .GC .GT . . . . .   | T . . . . .    | AG . . . . .            |
|           |                     | CDR1  |                | FW2                     |
| HSIGKLO12 | TTGC                | CGGGCAAGTCAGACGATTAGCAGCTATTAAAT                                |                | TGGTATCAGCAGAAACAGGGAAA |
| SP #      | 12                  | . . . . .   | GC . . . . .   | A . . . . .             |
|           | 20                  | . . . . .   | GC . . . . .   | A . . . . .             |
|           | 18                  | . . . . .   | G GC . . . . . | C . . . . .             |
|           | 14                  | . . . . .   | A . . . . .    | AA . . . . .            |
|           | 13                  | . . . . .   | A . . . . .    | C . . . . .             |
|           | 16                  | . . . . .   | GA . . . . .   | T . . . . .             |
|           | 17                  | . . . . .   | G . . . . .    | AT . . . . .            |
|           |                     | CDR2  |                |                         |
| HSIGKLO12 | GCCCTAAGCTCTGATCTAT | GCTGCATCCAGTTTGCAAAGT   |                | GGGTCCTCATCAAGTTCAA     |
| SP #      | 12                  | . . . . .   | T . . . . .    | . . . . .               |
|           | 20                  | . . . . .   | T . . . . .    | . . . . .               |
|           | 18                  | . . . . .   | C . . . . .    | A . . . . .             |
|           | 14                  | . . . . .   | G . . . . .    | A . . . . .             |
|           | 13                  | . . . . .   | T . . . . .    | C . . . . .             |
|           | 16                  | . . . . .   | AC . . . . .   | G . . . . .             |
|           | 17                  | . . . . .   | A . . . . .    | C . . . . .             |
|           |                     | FW3   |                |                         |
| HSIGKLO12 |                     | GTGGCACTGGATCTGGCAGAGATTTCACCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGC |                | AA                      |
| SP #      | 12                  | . . . . .   | T . . . . .    | G . . . . .             |
|           | 20                  | . . . . .   | T . . . . .    | G . . . . .             |
|           | 18                  | . . . . .   | T . . . . .    | C . . . . .             |
|           | 14                  | . . . . .   | T . . . . .    | C . . . . .             |
|           | 13                  | . . . . .   | C . . . . .    | C . . . . .             |
|           | 16                  | . . . . .   | C . . . . .    | G . . . . .             |
|           | 17                  | . . . . .   | C . . . . .    | A . . . . .             |
|           |                     | CDR3  |                |                         |
| HSIGKLO12 | CTTACTACTGT         | CAACAGAGTTACAGTACCCCT   |                |                         |
| SP #      | 12                  | . . . . .   | GA . . . . .   | GTG                     |
|           | 20                  | . . . . .   | GA . . . . .   | G                       |
|           | 18                  | . . . . .   | T . . . . .    | G                       |
|           | 14                  | . . . . .   | T . . . . .    | G                       |
|           | 13                  | . . . . .   | C . . . . .    | G                       |
|           | 16                  | . . . . .   | C . . . . .    | G                       |
|           | 17                  | . . . . .   | C . . . . .    | G                       |

#### Affinities for TPO of selected Fab

We expressed and purified the proteins for two of the newly isolated Fab clones, SP4.6 and SP1.20. SP4.6 was selected because of its distinctive H chain and SP1.20 because its L chain was the least mutated from the putative germline gene. Purified SP1.2 was already available (5). The affinities for TPO of the SP1.20 and SP4.6 Fab, calculated by Scatchard analysis (13) (Fig. 5), are very similar to each other ( $K_d$ ,  $1.0 \pm 0.2 \times 10^{-10}$  M and  $1.4 \pm 0.3 \times 10^{-10}$  M, respectively) and to that of SP1.2 ( $0.8 \pm 0.1 \times 10^{-10}$  M) (means  $\pm$  SEM).

#### Binding domains on TPO for SP Fab

To determine whether there was overlap in the domains on TPO recognized by SP4.6, SP1.20, and SP1.2, we performed studies with an immobilized SP1.2 Fab. As expected, preincubation of  $^{125}$ I-TPO with increasing concentrations of free SP1.2 inhibited the subsequent binding of the Ag to the immobilized SP1.2 (Fig. 6). The SP4.6 and SP1.20 Fab were equally effective, indicating that the

binding domains of all three Fab overlapped. No competition was observed with another anti-TPO Fab, TR1.9, cloned from another patient.<sup>4</sup>

#### Discussion

In the present study, we chose a single H or L chain already known to confer high affinity ( $\sim 10^{-10}$  M) specific binding for a large (107-kDa) protein autoantigen, TPO. We used this SP1.2 H (or SP1.2 L) chain to search for other L (or H) chains that could form a Fab capable of binding TPO. That is, we "spun the wheel" of the H and L chain repertoire of activated B cells infiltrating the patient's thyroid gland. As expected, the frequency of TPO-binding clones in the libraries generated by this biased recombination (1:500 for SP1.2 H  $\times$  parent L chain and 1:5000 for SP1.2 L  $\times$  parent H chain) was higher than in the original random combinatorial library (1:60,000) (4).

<sup>4</sup> Chazenbalk, G. D., Portolano, S., Russo, D., Hutchinson, J. S., Rapoport, B., McLachlan, S. "Human organ-specific autoimmune disease: molecular cloning and expression of an autoantibody gene repertoire." *Submitted for publication*.

**A**

|           | FW1                    | CDR1          | FW2            | CDR2     |
|-----------|------------------------|---------------|----------------|----------|
| HSIGKLO12 | DIVMTQSPSSLSASVGDRTITC | RASQSISSYLN   | WYQKPGKAPKLLIY | AASSLQS  |
| SP # .12  | EL...G.....            | ...A...       | ...K.....      | S.....   |
| .20       | EL.....                | ...A...       | ...K.....      | S.....   |
| .18       | EL.....E.....          | ...RA..T...   | ...R...N...    | GT.T...  |
| .14       | EL.....S.....          | ...N.GK...    | ...R.....E...  | GT.T...  |
| .13       | EL.....                | ...T..T..R... | ...I.....F     | A.....T  |
| .16       | EL.....                | ...D..R...    | ...D.....H     | G..T..E. |
| .17       | EL.....E..T.....       | ...EN..R.S.   | ...Q.....S     | ...T...  |

|           | FW3                             | CDR3      |
|-----------|---------------------------------|-----------|
| HSIGKLO12 | GVPSRFSGSGSGTDFTLTISLQPEDFATYYC | QQSYSTP   |
| SP # .12  | .....                           | ...D..    |
| .20       | .....                           | .....     |
| .18       | .....F.....                     | ...F...S. |
| .14       | .....F.....                     | ...F...S. |
| .13       | ...G.....T..D...                | .....     |
| .16       | ...G.....Y.....                 | .....     |
| .17       | .....H...N...G.....             | ..T..S.   |

**B**

|          | CDR3       | FW4                               |
|----------|------------|-----------------------------------|
| SP # .12 | GACACGTTTC | GGCCACGGGACCAAGGTGGAATCAAACTCAACT |
| .21      | CCG..T...  | ...CT.....GA.....G.....           |
| .20      | TGC.....   | .....                             |
| .18      | T...T...   | ...G.....C...G..AG.....           |
| .14      | T...T...   | ...G.....C...G..AG.....           |
| .13      | T...T..T   | ...G.....C...G.....G              |
| .16      | TT...T..T  | ...G.....C...G.....G              |
| .17      | TT...T..T  | ...G.....C...G.....G              |

**C**

|          | CDR3 | FW4          |     |
|----------|------|--------------|-----|
| SP # .12 | DTF  | GHGTVKVEIKRT | JK1 |
| .21      | P..  | .P..R..V...  | JK? |
| .20      | W..  | .....        | JK1 |
| .18      | Y..  | .Q...L..E..  | JK2 |
| .14      | Y..  | .Q...L..E..  | JK2 |
| .13      | Y..  | .Q...L.....  | JK2 |
| .16      | F..  | .Q...L.....  | JK2 |
| .17      | F..  | .Q...L.....  | JK2 |

**FIGURE 4.** A, Derived amino acid sequences of  $V_{\kappa}$  regions of anti-TPO Fab SP1.12 through SP1.22, compared with the closest germline gene, HSIGKLO12 (7). B and C, nucleotide (B) and derived amino acid (C) sequences of the  $J_{\kappa}$  regions of SP1.12 through SP1.22. Dots, identical nucleotides. CDR are indicated according to Kabat et al. (26).

However, the frequency was still lower (Table I) than would be the case if promiscuous binding to a variety of H or L chains was compatible with specific Ag binding.

The antibody repertoire in thyroid tissue B cells of patients with autoimmune thyroid disease is relevant to this discussion. This tissue is enriched, compared with draining lymph nodes and peripheral blood, in B cells actively secreting autoantibodies to the three major thyroid autoantigens, i.e., TPO, thyroglobulin, and the thyrotropin receptor (reviewed in Reference 18). This bias makes even more remarkable the paucity of H and L chains from this patient that are capable of combining with the preselected L or H chain to form a functional TPO binding site. For example, frequencies of 1:50 for a functional H chain have been reported in libraries from a mouse immunized with influenza hemagglutinin or in a human immunized with tetanus toxoid (8).

Nucleotide sequence analysis of the H and L chains of the new TPO-binding clones reveals even more restriction. Thus, with the SP1.2 H chain, all 11 new clones utilized L chains from the same  $V_{\kappa}1$  family germline gene. This

germline gene was also used by the three other TPO Fab already described (4, 5). Amino acid substitutions predominate in the CDR regions. Overall, taking into account the  $V_{\kappa}$  and  $J_{\kappa}$  regions of the L chains of 11 new clones and the previously described SP1.2, SP1.4, and SP1.5 (5), only 10 were distinct, because several were identical to the SP1.2 L chain or to each other.

Additional evidence for restriction was the very limited variety of H chains "captured" by the SP1.2 L chain in generating new TPO-binding clones. Five of the six clones were very closely related to the SP1.2 H chain, which is also shared by the previously identified SP1.4 and SP1.5 clones (5). However, unlike the L chains, we did isolate one H chain, SP4.6, that differs from all others in the following respects: (i) there are 24 amino acid differences between the  $V_H$  regions of SP4.6 and SP1.2, although both may be derived from the same  $V_H1$  germline gene, hv1L1; (ii) the D region is totally distinct; (iii) SP4.6 uses a different J region; and (iv) SP4.6 belongs to the IgG4 subclass. The SP4.6 H chain is more rare in the parent




FIGURE 5. Scatchard analysis (see *Materials and Methods*) of the affinities of SP1.2, SP4.6, and SP1.20 for TPO. One of three representative experiments is shown for each Fab.




FIGURE 6. Binding domains on TPO for the SP1.2, SP4.6, and SP1.20 Fab.  $^{125}\text{I}$ -TPO was preincubated in the absence or presence of increasing concentrations of SP4.6, SP1.20, and SP1.2 (Free F(ab)). Fab TR1.9 was obtained from another patient.<sup>4</sup> The ability of these complexes to bind to immobilized SP1.2 was then determined. The results are expressed as percentage of  $^{125}\text{I}$ -TPO bound after subtraction of background values ( $\sim 2\%$ ) obtained by using buffer alone.

library than is SP1.2 and related H chains, possibly because the oligonucleotide primer used to generate this library is suboptimal for IgG4. It is likely that the SP4.6 H chain was only found because of the bias introduced by the roulette approach.

In addition to providing data on the frequency and characterization of TPO-binding H and L chain combinations, our study illustrates important features with respect to antibody affinity and binding domains. These TPO autoantibodies have affinities for Ag several orders of magnitude greater than those reported for naturally occurring, polyreactive autoantibodies ( $K_d$ ,  $10^{-3}$  to  $10^{-7}$  M) (19). It is possible that the screening approach that we used permits identification only of clones capable of high affinity TPO binding. Clones with lower affinity for TPO may, in the

future, be identified more easily by using the phage display technique (20). However, this is not our present goal because TPO autoantibodies in patients' sera have high affinities (21), similar to our recombinant Fab.

It is of interest that the affinity of SP1.20 is high (similar to that of SP1.2) even though its  $V_H$  chain is less mutated than that of SP1.2 (95% and 81% homology, respectively, to the germline gene). Assuming that both genes are, indeed, derived from HSIKLO12, it is possible that affinity maturation of the L chain does not play a critical role in determining the affinity of the Fab for TPO.

The most unexpected finding in our study, in our estimation, concerns the TPO-binding domains of the SP Fab. Thus, in accordance with the data of Radic et al. (22) concerning murine autoantibodies to DNA, it was anticipated that both the SP1.2 and SP1.20 Fab, which have the same H chain and have closely related L chains, would interact with overlapping epitopes and bind to the same domain on TPO. However, a similar domain on TPO was recognized by both SP4.6 and SP1.2, despite the fact that their V, D, and J regions are quite different. This finding contrasts with the data of Martin et al. (23), who found that polyspecific autoantibody activity could only be generated with a specific D region. Our data were also unexpected in view of the extensive analysis by Kabat and Wu (24) of V region H and L chain combinations, which suggested  $V_H$  dominance in defining antibody specificity in many instances. However, as also suggested by Kabat and Wu (24) for some antibodies and as demonstrated by Smith-Gill et al. (25) for some murine antibodies to lysozyme, our findings raise the possibility that the L chain is critical in defining epitope specificity, even in the presence of completely different D regions and nonidentical  $V_H$  regions. With respect to our clones, it is possible that molecular modeling of SP4.6 and SP1.2 would reveal regions of similarity in their three-dimensional conformations, despite the dissimilarities in their CDR, particularly CDR3.



## References

1. McLachlan, S. M., and B. Rapoport. 1992. The molecular biology of thyroid peroxidase: cloning, expression and role as autoantigen in autoimmune thyroid disease. *Endocr. Rev.* 13:192.
2. Parkes, A. B., S. M. McLachlan, P. Bird, and B. Rees Smith. 1984. The distribution of microsomal and thyroglobulin antibody activity among the IgG subclasses. *Clin. Exp. Immunol.* 57:239.
3. Weetman, A. P., C. M. Black, S. B. Cohen, R. Tomlinson, J. P. Banga, and C. B. Reimer. 1989. Affinity purification of IgG subclasses and the distribution of thyroid auto-antibody reactivity in Hashimoto's thyroiditis. *Scand. J. Immunol.* 30:73.
4. Portolano, S., P. Seto, G. D. Chazenbalk, Y. Nagayama, S. M. McLachlan, and B. Rapoport. 1991. A human Fab fragment specific for thyroid peroxidase generated by cloning thyroid lymphocyte-derived immunoglobulin genes in a bacteriophage *lambda* library. *Biochem. Biophys. Res. Commun.* 179:372.
5. Portolano, S., G. D. Chazenbalk, P. Seto, J. S. Hutchison, B. Rapoport, and S. M. McLachlan. 1992. Recognition by recombinant autoimmune thyroid disease-derived Fab fragments of a dominant conformational epitope on human thyroid peroxidase. *J. Clin. Invest.* 90:720.
6. Huse, W. D., L. Sastry, S. A. Iverson, A. S. Kang, M. Alting-Mees, D. R. Burton, S. J. Benkovic, and R. A. Lerner. 1989. Generation of a large combinatorial library of the immunoglobulin repertoire in phage *lambda*. *Science* 246:1275.
7. Pargent, W., A. Meindl, R. Thiebe, S. Mitzel, and H. G. Zachau. 1991. The human immunoglobulin  $\kappa$  locus: characterization of the duplicated O regions. *Eur. J. Immunol.* 21:1821.
8. Kang, A. S., T. M. Jones, and D. R. Burton. 1991. Antibody redesign by chain shuffling from random combinatorial immunoglobulin libraries. *Proc. Natl. Acad. Sci. USA* 88:11120.
9. Maniatis, T., E. F. Fritsch, and J. Sambrook. 1982. *Molecular Cloning. A Laboratory Manual*. Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory, NY.
10. Foti, D., K. D. Kaufman, G. Chazenbalk, and B. Rapoport. 1990. Generation of a biologically-active, secreted form of human thyroid peroxidase by site-directed mutagenesis. *Mol. Endocrinol.* 4:786.
11. Salacinski, P. R. P., C. McLean, J. E. C. Sykes, V. V. Clement-Jones, and P. J. Lowry. 1981. Iodination of proteins, glycoproteins, and peptides using a solid-phase oxidizing agent, 1,3,4,6-tetrachloro-3 $\alpha$ ,6 $\alpha$ -diphenyl glycoluril (Iodogen). *Anal. Biochem.* 117:136.
12. Sanger, F., S. Nicklen, and A. R. Coulson. 1977. DNA sequencing with chain terminating inhibitors. *Proc. Natl. Acad. Sci. USA* 74:5463.
13. Scatchard, G. 1949. The attractions of proteins for small molecules and ions. *Ann. N. Y. Acad. Sci.* 51:660.
14. Berman, J. E., S. J. Mellis, R. Pollock, C. L. Smith, H. Suh, B. Heinke, C. Kowal, U. Surti, L. Chess, C. R. Cantor, and F. W. Alt. 1988. Content and organization of the human Ig V<sub>H</sub> locus: definition of three new V<sub>H</sub> families and linkage to the Ig C<sub>H</sub> locus. *EMBO J.* 7:727.
15. Pascual, V., and J. D. Capra. 1991. Human immunoglobulin heavy chain variable region genes: organization, polymorphism and expression. *Adv. Immunol.* 49:1.
16. Olee, T., E. W. Lu, D.-F. Huang, R. W. Soto-Gil, M. Deftos, F. Kozin, D. A. Carson, and P. P. Chen. 1992. Genetic analysis of self-associating immunoglobulin G rheumatoid factors from two rheumatoid synovia implicates an antigen-driven response. *J. Exp. Med.* 1750:8310-842.
17. Kato, S., K. Tachibana, N. Takayama, H. Kataoka, M. C. Yoshida, and T. Takano. 1991. Genetic recombination in a chromosomal translocation t(2;8)(p11;q24) of a Burkitt's lymphoma cell line, KOBK101. *Gene* 97:239.
18. Rees Smith, B., S. M. McLachlan, and J. Furmaniak. 1988. Autoantibodies to the thyrotropin receptor. *Endocr. Rev.* 9:106.
19. Nakamura, M., S. E. Burastero, Y. Ueki, J. W. Larrick, A. L. Notkins, and P. Casali. 1988. Probing the normal and autoimmune B cell repertoire with Epstein-Barr virus: frequency of B cells producing monoreactive high affinity autoantibodies in patients with Hashimoto's disease and systemic lupus erythematosus. *J. Immunol.* 141:4165.
20. Kang, A. S., C. F. Barbas, K. D. Janda, S. J. Benkovic, and R. A. Lerner. 1991. Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surfaces. *Proc. Natl. Acad. Sci. USA* 88:4363.
21. Beever, K., J. Bradbury, D. Phillips, S. M. McLachlan, C. Pegg, A. Goral, W. Overbeck, G. Feifel, and B. Rees Smith. 1989. Highly sensitive assays of autoantibodies to thyroglobulin and to thyroid peroxidase. *Clin. Chem.* 35:1949.
22. Radic, M. Z., M. A. Mascelli, J. Erikson, H. Shan, and M. Weigert. 1991. Ig H and L chain contributions to autoimmune specificities. *J. Immunol.* 146:176.
23. Martin, T., S. F. Duffy, D. A. Carson, and T. A. Kipps. 1992. Evidence for somatic selection of natural autoantibodies. *J. Exp. Med.* 175:983.
24. Kabat, E. A., and T. T. Wu. 1991. Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. *J. Immunol.* 147:1709.
25. Smith-Gill, S. J., P. A. Hamel, T. B. Lovoie, and K. J. Dorning. 1987. Contributions of immunoglobulin heavy and light chains to antibody specificity for lysozyme and two haptens. *J. Immunol.* 139:4135.
26. Kabat, E. A., T. T. Wu, H. M. Perry, K. S. Gottesman, and C. Foeller. 1991. *Sequences of Proteins of Immunological Interest*. United States Department of Health and Human Services, Bethesda MD.